Delay In Forest Drug FDA Action Date
Forest Laboratories, Inc. (NYSE:FRX) will be facing a delay where the approvability status of one of its pipeline candidates is concerned. The company recently announced that the US Food and Drug Administration (FDA) has extended its action date for aclidinium bromide by three months. Forest Labs and partner Almirall are looking to get aclidinium bromide [...]
Forest Laboratories, Inc. (NYSE:FRX) will be facing a delay where the approvability status of one of its pipeline candidates is concerned. The company recently announced that the US Food and Drug Administration (FDA) has extended its action date for aclidinium bromide by three months.
Forest Labs and partner Almirall are looking to get aclidinium bromide approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
We note that last month, aclidinium bromide had received … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards